Objective To evaluate retrospectively the reporting quality of animal experiments published in Chinese journals adhering to the Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines. Methods We searched databases including CNKI, WanFang, VIP and CBM by July, 2018. Two well-trained reviewers screened and extracted articles independently. The ARRIVE guidelines were used to assess the quality of animal experiment reports. The compliance rate of every item was analyzed according to different published time.Results 4342 studies were included finally, of which 73.03% had been cited ≤ 5 times, only 29.04% (1261/4342) were published in journals of Chinese Science Citation Database. The assessment results showed that the compliance rate of more than half of sub-items (51.28%, 20/39) was less than 50% and 65.00% (13/20) of sub-items was less than 10%.Conclusion The reporting quality of animal experiments in Chinese journals is generally lower than moderate level. Along with the publication of the ARRIVE guidelines in 2010, the compliance rate of most items in the ARRIVE guidelines has been improved to some extent. However, some specific items of methods, results and discussion were not still reported sufficiently and integrally. Therefore, it is necessary to popularize the ARRIVE guidelines, advocate researchers to adhere to the ARRIVE guidelines in the future and especially to promote the use of the ARRIVE guidelines in specialized journals, so as to promote the design, implementation and reporting of animal experiments, and ultimately improve their quality.

Objective: To explore the application of nanoscale ultrasound contrast agent mediating PEG10 antisense gene transfection in the treatment of hepatocellular carcinoma. Methods: The optimal concentration and ultrasound parameters of nanoscale ultrasound contrast agent were screened via cell viability assay. PEG10 antisense oligodeoxynucleotide (ASODN) and fluorescein-labeled specific ligand galactose terminal glycol-poly-L-lysine (G-PLL) were combined with nanoscale ultrasound contrast agent. Then PEG10 ASODN was transfected into human HepG2 cells under ultrasonic irradiation. RT-PCR was used to detect the expression of PEG10. MTT assay was conducted to assess the proliferation inhibition of hepatocellular carcinoma cells. And the tumor inhibition rate in vivo was analyzed by establishing the nude mice transplantation tumor model. Results: Of all the conjugates, the optimal molar ratio of PEG10 ASODN to G-PLL was 1:2. The best parameters after screening showed that nanoscale ultrasound contrast agent of 15% microbubble concentration and ultrasound exposure at 1.5 MHz, 1.0 W/cm 2 , and 10% duty cycle for 60 s had no significant influence on the viability of HepG2 cells (P > 0 05). Compared with other groups, PEG10 ASODN+G-PLL+microbubble group had the weakest PEG10 expression, the most significant cell growth inhibition, and the highest tumor inhibition rate up to 38.5%. Conclusion: Under ultrasonic irradiation, G-PLL conjugating nanoscale microbubble ultrasound contrast agent and antisense gene can effectively enhance the inhibition of antisense gene on PEG10 expression, which has targetedly inhibitory effect on hepatoma cells. This is expected to provide an efficient means for the treatment of hepatocellular carcinoma.